StoxMankind Pharma vs Lupin: share price & financials comparison
NSE: MANKIND vs LUPIN · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Mankind Pharma vs Lupin at a glance
Mankind Pharma (MANKIND) has a market capitalisation of ₹1,04,902 Cr, against ₹90,916 Cr for Lupin (LUPIN). Over the past year Mankind Pharma has returned +3.9%, compared with +1.6% for Lupin. On valuation, Lupin trades at a lower P/E of 17.5 versus 46.7. Lupin earns a higher return on equity (21.6% vs 12.8%). Mankind Pharma comes out ahead on growth, momentum and technicals. Lupin comes out ahead on size, valuation, profitability and financial health. Across the scored metrics below, Mankind Pharma leads on 7 and Lupin on 9. On StoxGud's 10-point checklist, Mankind Pharma scores 7/10 and Lupin scores 7/10.
| Metric | Mankind Pharma | Lupin |
|---|---|---|
| Size | ||
| Market cap | ₹1,04,902 Cr | ₹90,916 Cr |
| Revenue (latest FY) | ₹14,278 Cr | ₹27,958 Cr |
| Net profit (latest FY) | ₹1,913 Cr | ₹5,333 Cr |
| Valuation | ||
| P/E | 46.7 | 17.5 |
| P/B | 5.97 | 3.78 |
| Dividend yield | 0.04% | 0.60% |
| Profitability | ||
| Return on equity | 12.8% | 21.6% |
| Net profit margin | 14.6% | 16.9% |
| Operating margin | 26.5% | 30.1% |
| Growth | ||
| Revenue growth (YoY) | +17.3% | +11.1% |
| Net profit growth (YoY) | +39.1% | -21.8% |
| Revenue CAGR (multi-year) | +17.7% | +13.0% |
| Financial health | ||
| Debt to equity | 0.31 | 0.23 |
| Momentum | ||
| 1-month return | +1.6% | -1.2% |
| 1-year return | +3.9% | +1.6% |
| 3-year CAGR | +13.0% | +18.3% |
| 5-year CAGR | — | +16.4% |
| 10-year CAGR | — | +2.7% |
| Distance from 52W high | -3.0% | -20.9% |
| Technicals | ||
| RSI (14) | 72 | 55 |
| Price vs 200-day avg | +9.5% | -11.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Mankind Pharma | Lupin |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Mankind Pharma or Lupin?
Mankind Pharma has a market cap of ₹1,04,902 Cr and Lupin has a market cap of ₹90,916 Cr as of 06 Nov 2026.
Which has a lower P/E, Mankind Pharma or Lupin?
Lupin has the lower P/E: Mankind Pharma trades at 46.7 and Lupin at 17.5.
Which gave better returns in the last year, Mankind Pharma or Lupin?
Mankind Pharma did better: Mankind Pharma returned +3.9% and Lupin returned +1.6% over one year.
Is Mankind Pharma or Lupin a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Mankind Pharma scores 7/10 and Lupin scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.